Quarterly Result13 May 2026, 01:47 pm
Onesource FY26: Revenue ₹14,216 Mn, EBITDA ₹3,042 Mn; FY28 Guidance Reaffirmed
AI Summary
Onesource Specialty Pharma Ltd announced its FY26 results, reporting revenues of ₹14,216 million and EBITDA of ₹3,042 million. Q4FY26 revenues stood at ₹4,282 million, up 47% QoQ, with EBITDA at ₹919 million, a 5x+ increase QoQ. The company reaffirmed its FY28 guidance of ~$400 million in organic revenue with ~40% EBITDA margin. Strong Q4 performance was driven by broad business momentum and India semaglutide launches. Adjusted PAT for FY26 was ₹739 million.
Key Highlights
- FY26 Revenue at ₹14,216 million, down 2% YoY.
- Q4FY26 Revenue up 47% QoQ to ₹4,282 million.
- Q4FY26 EBITDA increased over 5x QoQ to ₹919 million.
- FY28 guidance reaffirmed: ~$400 million revenue, ~40% EBITDA margin.
- Successful semaglutide launches in India boosted Q4 performance.